FDA Plans to Get Tough On Clinical Trials That Don’t Include Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

WASHINGTON-The FDA has proposed a new regulation that would make sure pharmaceutical companies comply with a 1993 order to include women in all phases of drug testing. An examination of some 4,000 trials done in the last three years showed that approximately one quarter still excluded women of childbearing age solely because they could become pregnant during the trial.

WASHINGTON—The FDA has proposed a new regulation that would make sure pharmaceutical companies comply with a 1993 order to include women in all phases of drug testing. An examination of some 4,000 trials done in the last three years showed that approximately one quarter still excluded women of childbearing age solely because they could become pregnant during the trial.

The new rule would allow the FDA to stop or prevent clinical trials of agents for use in serious or life-threatening conditions if they exclude women of childbearing age. The rule would apply even to drugs suspected of causing birth defects. The FDA will decide whether to finalize the measure after a 90-day period for public comment.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content